Schizophrenia Update: Navigating the Latest in Research and Treatment - Module 2: Advances in Long-Acting Injectables

Schizophrenia affects millions globally, and while oral antipsychotics are commonly used, adherence is often hindered by side effects and complicated dosing schedules. In Module 2 of this series, we explore the benefits of long-acting injectables (LAIs), such as less frequent dosing, steadier blood concentrations, and improved patient tolerance. Watch this video to discover how the latest LAI formulations can improve treatment adherence and patient outcomes. Get expert insights on optimizing schizophrenia care with LAIs.

STATEMENT OF NEED

Schizophrenia, a debilitating mental illness characterized by psychotic symptoms such as hallucinations and delusions, affects more than 24 million people throughout the world (National Institute of Mental Health, 2024; Wang et al, 2024). The primary form of treatment for schizophrenia is oral antipsychotic drugs, but these treatments are often associated with suboptimal adherence due to side effects and dosing schedules. Long-acting injectables (LAIs) are a novel formulation of antipsychotics with advantages such as less frequent dosing and the potential for improved adherence due to slower absorption and steadier blood concentrations, which may result in less toxicity and better tolerance (Wang et al, 2024). In recent years, more LAI formulations have become available with extended indications, expanded dose intervals, and improved initiation strategies, but these are still underutilized (Wang et al, 2024; Højlund & Correll, 2023). It is crucial for members of the interdisciplinary care team to stay up to date on LAIs in order to improve outcomes for patients. In Module 2 of this activity, Dr. Christoph U. Correll, Professor of Psychiatry and Molecular Medicine at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, and Professor and Chair of the Department of Child and Adolescent Psychiatry at Charité – University Medicine in Berlin, Germany, will provide insights into improving treatment adherence through the use of LAIs for schizophrenia.

TARGET AUDIENCE

Psychiatrists, psychiatric nurse practitioners, psychiatric physician assistants/associates, psychiatric mental health nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with schizophrenia.

Upon completion of this activity, participants should be able to

• Assess the indications, efficacy, and safety of novel and emerging LAI formulations of antipsychotics for the treatment of schizophrenia

PROVIDED BY

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 2/17/26. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development

A maximum of 0.5 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.5 ANCC contact hours of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 0.5 ANCC contact hours. 

Continuing Pharmacy Education

i3 Health has approved this knowledge-based activity for 0.5 ACPE CE hours. The Universal Activity Number for this activity is JA0008128-0000-25-005-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion. 

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Christoph U. Correll, MD, discloses that he has served on an advisory board or panel for AbbVie, Allergan, Angelini, Boehringer Ingelheim, Bristol Meyers Squibb, Cerevel, Compass, Gedeon Richter, Janssen/J&J, Karuna, LB Pharma, Life Science, Lundbeck, MedInCell, Merck, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Rovi, Sage, Seqirus, Sunovion, Supernus, Teva, Vertex, and Viatris; that he has served as a consultant for AbbVie, Allergan, Angelini, Boehringer Ingelheim, Bristol Meyers Squibb, Cerevel, Compass, Denovo, Eli Lilly, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, Karuna, Kuleon Biosciences, LB Pharma, Life Science; Lundbeck, MedInCell, Medlink, Merck, Mindpax, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, Sunovion, Supernus, Teva, Vertex, and Viatris; that he has received grants/research support from Boehringer-Ingelheim, Janssen, and Takeda; and that he is a stock/shareholder with Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, and Terran.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must watch the video and submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CPE ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME/NCPD/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.